Treating patients like individuals

Research

Papers

Mould DR, Upton RN, Wojciechowski J, Phan BL, Tse S, Dubinsky MC: Dashboards for the therapeutic monoclonal antibodies. AAPS J. Forthcoming 2018.       

 

Eser A, Primas C, Reinisch S, Vogelsang H, Novacek G, Mould DR, Reinisch W. Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System. J Clin Pharmacol. 2018 Jan 30. doi: 10.1002/jcph.1069. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/29381220

 

Kevans D, Murthy S, Mould DR, Silverberg MS. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. J Crohns Colitis. 2018;12(6):662-669. https://www.ncbi.nlm.nih.gov/pubmed/29659758

 

Wojciechowski J, Upton RN, Mould DR, Wiese MD, Foster DJR. Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies. AAPS J. 2017;19(4):1136-1147. https://www.ncbi.nlm.nih.gov/pubmed/28444562

 

Dubinsky MC, Phan BL, Singh N, Rabizadeh S, Mould DR. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients. AAPS J. 2017 ;19(1):215-222 https://www.ncbi.nlm.nih.gov/pubmed/27739008

 

Mould DR, D'Haens G, Upton RN. Clinical Decision Support Tools: The Evolution of a Revolution. Clin Pharmacol Ther. 2016 ;99(4):405-18 https://www.ncbi.nlm.nih.gov/pubmed/26785109

 

Mould DR, Dubinsky MC. Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J Clin Pharmacol. 2015;55 Suppl 3:S51-9 https://www.ncbi.nlm.nih.gov/pubmed/25707964